英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
qenuineness查看　qenuineness　在百度字典中的解释百度英翻中〔查看〕
qenuineness查看　qenuineness　在Google字典中的解释Google英翻中〔查看〕
qenuineness查看　qenuineness　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release . . .
    SHANGHAI, China and ROCKVILLE, MD , March 13, 2020 -- I-Mab Biopharma (Nasdaq: IMAB), (“I-Mab” or the “Company”), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced that
  • ir. i-mabbiopharma. com
    I-Mab’s mission is to bring transformational medicines to patients through innovation I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R D and global partnerships
  • I-Mab | SEC Filing
    I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area The Company s mission is to bring transformational medicines to patients around the world through drug innovation
  • I-Mab | 0000950170-24-108621 | 6-K
    The Investor Relations website contains information about I-Mab's business for stockholders, potential investors, and financial analysts
  • I-Mab | SEC Filing
    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8 (a) of the Securities Act of 1933 or until the Registration Statement shall become effective on
  • ir. i-mabbiopharma. com
    I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer I-Mab has established operatons in Rockville, Maryland, and Short Hills, New Jersey
  • I-Mab | SEC Filing
    I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases
  • I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
    I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey
  • I-Mab | I-Mab Strengthens Management Team Designed to Accelerate Global . . .
    I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases
  • ir. i-mabbiopharma. com
    About I-Mab I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development, and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases





中文字典-英文字典  2005-2009